RxDoctor Payments Data

Thomas Gillette, MD

Ophthalmology · Albuquerque, NMNPI 1013413475

Payments from drug & device makers

What this record shows

AbbVie accounts for 61.9% of it on its own, with 10 other manufacturers making up the rest.

$5,883in general payments, 2019–2025

Across 111 payments — averaging $53.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Alcon$1K
  • Rxsight Inc$258
  • Glaukos Corporation$159
  • Ocular Therapeutix, Inc.$148
  • Bausch & Lomb Americas Inc.$138
  • plus $466 from 5 others

What the payments were for

  • Travel & lodging$2,42541%
  • Food & beverage$3,45859%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,883 in reported general payments places this provider in the 85th percentile of 81 ophthalmology providers in New Mexico.

See all ophthalmology providers in New Mexico

Medicare billing

Part B allowed, 2024
$332,170
Medicare patients
969
Services billed
2,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine124$124,785
XiidraLifitegrast37$55,642
Cyclosporine50$24,685
MieboPerfluorohexyloctane/Pf22$18,597
LumiganBimatoprost27$16,325
Prednisolone Acetate395$13,356
Fluorometholone101$11,401
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$4,177
Latanoprost230$4,115
Ofloxacin271$3,363
Brimonidine Tartrate34$2,348
Tobramycin-DexamethasoneTobramycin/Dexamethasone20$1,604
Timolol Maleate86$984
Doxycycline Hyclate22$853
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat38$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$3,643$141,110151 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$138$74,23859 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 81 ophthalmology providers in New Mexico.

Other ophthalmology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →